JP2024501872A5 - - Google Patents
Info
- Publication number
- JP2024501872A5 JP2024501872A5 JP2023540488A JP2023540488A JP2024501872A5 JP 2024501872 A5 JP2024501872 A5 JP 2024501872A5 JP 2023540488 A JP2023540488 A JP 2023540488A JP 2023540488 A JP2023540488 A JP 2023540488A JP 2024501872 A5 JP2024501872 A5 JP 2024501872A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- complex according
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063133156P | 2020-12-31 | 2020-12-31 | |
| US63/133,156 | 2020-12-31 | ||
| US202163181439P | 2021-04-29 | 2021-04-29 | |
| US63/181,439 | 2021-04-29 | ||
| PCT/US2021/065624 WO2022147207A1 (en) | 2020-12-31 | 2021-12-30 | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026076157A Division JP2026133445A (ja) | 2020-12-31 | 2026-04-30 | 顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501872A JP2024501872A (ja) | 2024-01-16 |
| JP2024501872A5 true JP2024501872A5 (enExample) | 2025-01-14 |
| JP7860122B2 JP7860122B2 (ja) | 2026-05-15 |
Family
ID=82261078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540488A Active JP7860122B2 (ja) | 2020-12-31 | 2021-12-30 | 顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240110184A1 (enExample) |
| EP (1) | EP4271478A4 (enExample) |
| JP (1) | JP7860122B2 (enExample) |
| KR (1) | KR20230128314A (enExample) |
| CA (1) | CA3202826A1 (enExample) |
| IL (1) | IL304049A (enExample) |
| WO (1) | WO2022147207A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| US20260159835A1 (en) * | 2024-12-05 | 2026-06-11 | Soufflé Therapeutics, Inc. | Oligonucleotide-mediated knockdown of dux4 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3473270T5 (da) | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| MA49923A (fr) * | 2017-10-02 | 2020-06-24 | Res Inst Nationwide Childrens Hospital | Système de déciblage de miarn pour interférence spécifique d'un tissu |
| EP3830259A4 (en) * | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| CN114025805B (zh) * | 2019-06-07 | 2025-01-24 | 达因疗法公司 | 制备蛋白质-寡核苷酸复合物的方法 |
-
2021
- 2021-12-30 EP EP21916465.4A patent/EP4271478A4/en active Pending
- 2021-12-30 JP JP2023540488A patent/JP7860122B2/ja active Active
- 2021-12-30 WO PCT/US2021/065624 patent/WO2022147207A1/en not_active Ceased
- 2021-12-30 CA CA3202826A patent/CA3202826A1/en active Pending
- 2021-12-30 US US18/270,284 patent/US20240110184A1/en active Pending
- 2021-12-30 IL IL304049A patent/IL304049A/en unknown
- 2021-12-30 KR KR1020237025561A patent/KR20230128314A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510351A5 (enExample) | ||
| JP2023512442A5 (enExample) | ||
| JP2023512441A5 (enExample) | ||
| JP2023535078A5 (enExample) | ||
| JP2023535444A5 (enExample) | ||
| JP2023509793A5 (enExample) | ||
| JP2021532832A5 (enExample) | ||
| JP2021533197A5 (enExample) | ||
| JP2021533200A5 (enExample) | ||
| JP7803926B2 (ja) | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 | |
| JP2021533199A5 (enExample) | ||
| JP2024546436A5 (enExample) | ||
| JP2024525614A5 (enExample) | ||
| IL317871A (en) | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy | |
| JP2023510350A5 (enExample) | ||
| JP2024524222A5 (enExample) | ||
| JP2021533198A5 (enExample) | ||
| JP2025067909A5 (enExample) | ||
| JP2024527362A5 (enExample) | ||
| JP2024503609A5 (enExample) | ||
| JP2022174146A (ja) | 抗体－薬物コンジュゲート | |
| JP2023535073A5 (enExample) | ||
| JP2024525610A5 (enExample) | ||
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| JP2025512468A5 (enExample) |